Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial

Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page’s revision/version label was updated from v3.5.2 to v3.5.3, indicating a change to the site build rather than the clinical trial information shown to users.
    Difference
    0.0%
    Check dated 2026-04-24T17:13:03.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T14:01:58.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Posted trial results and updated study record dates were added to the page (Results First Posted 2024-11-14; Study Record Dates Updated 2024-11-14).
    Difference
    0.0%
    Check dated 2026-04-03T06:00:39.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Results data was added to the study page, including a 'Results First Posted' date (2024-11-14). Study record dates were updated accordingly.
    Difference
    0.0%
    Check dated 2026-03-27T02:36:21.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T23:56:50.000Z thumbnail image
  8. Check
    54 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.3, replacing Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T20:24:16.000Z thumbnail image

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.